Ted Buchan & Co’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Ted Buchan & Co’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,169	Closed	-$217K	–	89
2025 Q3	$217K	Sell	2,169 -90,585	-98%	-$8.16M	0.09%	79
2025 Q2	$7.69M	Buy	92,754 +7,235	+8%	+$577K	3.06%	10
2025 Q1	$6.94M	Buy	85,519 +288	+0.3%	+$25.7K	3.28%	11
2024 Q4	$7.68M	Sell	85,231 -4,977	-6%	-$482K	3.62%	10
2024 Q3	$8.91M	Sell	90,208 -5,322	-6%	-$523K	4.23%	8
2024 Q2	$8.86M	Buy	95,530 +1,348	+1%	+$121K	4.75%	5
2024 Q1	$8.94M	Sell	94,182 -305	-0.3%	-$28.3K	5.49%	5
2023 Q4	$8.44M	Buy	94,487 +477	+0.5%	+$35.4K	6.14%	4
2023 Q3	$6.86M	Buy	94,010 +912	+1%	+$72.8K	5.52%	6
2023 Q2	$7.75M	Buy	93,098 +4,677	+5%	+$391K	5.96%	5
2023 Q1	$6.74M	Buy	88,421 +73,229	+482%	+$6.08M	5.63%	6
2022 Q4	$1.26M	Buy	+15,192	New	+$1.23M	1.17%	17

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Ted Buchan & Co's XBI Position: Q4 2025 in Review

Ted Buchan & Co sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2025, closing a stake of 2,169 shares — an estimated $217K sold.

Ted Buchan & Co first reported a position in XBI in Q4 2022 and held it in 12 quarters. The position peaked at $8.94M in Q1 2024. 814 funds tracked by Wall St. Rank hold XBI as of Q4 2025.

Ted Buchan & Co reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2025 after selling out during the quarter.
Ted Buchan & Co sold 2,169 State Street SPDR S&P Biotech ETF shares in Q4 2025, an estimated $217K.
Ted Buchan & Co first reported a position in State Street SPDR S&P Biotech ETF in Q4 2022 and held it in 12 quarters.
Ted Buchan & Co's State Street SPDR S&P Biotech ETF position peaked at $8.94M in Q1 2024.
814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2025.

Based on Ted Buchan & Co's 13F filing for Q4 2025, filed 11 Feb 2026.